For one of Dr. Edelman’s patients, Mounjaro was a life-changing medication that helped address several health challenges she struggled with for years. She shares her journey taking Mounjaro for the last six months, and explains why it’s been her “miracle drug”.
read more →
One of Dr. Edelman’s patients with prediabetes shares her experience trying this popular drug. She touches on how it affected her diabetes, what it did to her sugar cravings, and how she dealt with side effects. You decide…is it worth the hype?
read more →
Most people have struggled with weight in some way at one time or another. If you have some pounds to lose and aren’t sure where to begin, there are lots of tools and medication options available now, including a newer GLP-1 RA that also helps control blood sugars.
read more →
Drs. Edelman and Pettus discuss the novel type 2 medicine Mounjaro, a combination GLP-1/GIP that helps lower A1c and promote weight loss.
read more →
One of the most common challenges for people with diabetes is trying to prevent blood sugars from shooting up after meals. Drs. E and P have been managing spikes for over 75 years between the two of ’em, and they offer clear-cut suggestions on how to keep post-meal highs at bay.
read more →
The FDA recently approved a novel medication called Mounjaro. See how this once-weekly therapy works to significantly lower A1c and promote weight loss in people with type 2 diabetes.
read more →
Medicare recently launched a new program called the Medicare Part D Senior Savings Model Program to test the impact of giving Medicare beneficiaries 65 and older an increased choice of Part D plans with no deductible and a max copay of $35 per month for insulin and fixed-ratio combination GLP-1 RAs Soliqua and Xultophy.
read more →
The FDA recently approved Wegovy, the first and only once-weekly injection for chronic weight management in adults.
read more →
Dr. Edelman clarifies how SGLTs and GLP-1s affect insulin use, and whether or not they cause hypoglycemia.
read more →
Our international panel of diabetes experts discussed highlights from the ADA’s Scientific Sessions, and lead a Q&A on some of the most important advances in diabetes.
read more →
